Gene combination raises broad human immunodeficiency virus-specific cytotoxicity

Human Gene Therapy

Volumn 12, Issue 13, 2001, Pages 1623-1637

  Calarota, Sandra A ^a   Kjerrstrm, Anne ^a   Wahren, Britta ^a   Islam, Khalid B ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; LAMIVUDINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEF PROTEIN; PLASMID DNA; REV PROTEIN; TRANSACTIVATOR PROTEIN; ZIDOVUDINE;

ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DOSE TIME EFFECT RELATION; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTOTOXICITY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MEMORY CELL; MURINE LEUKEMIA VIRUS; NONHUMAN; PROLYMPHOCYTE; REGULATOR GENE; SIDE EFFECT; TARGET CELL; VACCINIA VIRUS; VIRUS GENOME;

AIDS VACCINES; CD4 LYMPHOCYTE COUNT; CPG ISLANDS; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION; GENE PRODUCTS, NEF; GENE PRODUCTS, REV; GENE PRODUCTS, TAT; GENES, VIRAL; GENETIC VECTORS; HELA CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; LEUKEMIA VIRUS, MURINE; LYMPHOCYTE ACTIVATION; PLASMIDS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, DNA; VACCINIA VIRUS;

EID: 0034803909     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340152528129     Document Type: Article

References (36)

1. Dose-response resistance to HIV-1/MuLV pseudotype virus ex vivo in a hairpin ribozyme transgenic mouse model
2. An inhibitor of HIV-1 protease modulates proteosome activity, antigen presentation, and T cell responses
3. Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial
4. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of β-chemokines
5. Compatibility of plasmids expressing different antigens in a single DNA vaccine formulation
6. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients
7. Immune responses in asymptomatic HIV-1 infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment
8. Genetic immunization: A new era in vaccines and immune therapeutics
9. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy
10. Mechanism and function of a newly identified CpG DNA motif in human primary B cells
11. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
12. Epitope mapping of the HIV-1 Gag region with monoclonal antibodies
13. Nucleic acid vaccination with HIV regulatory genes: A combination of HIV-1 genes in separate plasmids induces strong immune responses
14. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes
15. Expression of HIV regulatory DNA vaccine constructs
16. Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines
17. Contribution of CpG motifs to the immunogenicity of DNA vaccines
18. CpG motifs as immune adjuvants
19. CpG DNA augments the immunogenicity of plasmid DNA vaccines
20. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs
21. Induction of specific T-cell responses in HIV infection
22. Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses
23. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response
24. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
25. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease
26. Quantification of HIV-specific cytotoxic T lymphocytes and plasma viral load of viral RNA
27. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy
28. Expression kinetics and subcellular localization of HIV-1 regulatory proteins Nef, Tat and Rev in acutely and chronically infected lymphoid cell lines
29. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants
30. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
31. Human immunodeficiency virus pseudotypes with expanded cellular and species tropism
32. Computer aided design and evaluation of limiting and serial dilution experiments
33. Bacterial CpG DNA activates immune cells to signal infectious danger
34. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160
35. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine